Cosentyx (Secukinumab) 150mg/1mL China | IL-17A Inhibitor | GLT
Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.
- We reply within 24 hours with pricing, availability & COA
- Serves individuals and institutions worldwide
Prefer email? [email protected] · +86 15234153837
Generic Information: Cosentyx (China-Mainland)
Cosentyx (可善挺, secukinumab) is the China-Mainland brand of secukinumab, a fully human IgG1 monoclonal antibody developed by Novartis that selectively inhibits interleukin-17A (IL-17A). It is supplied in two strengths: a 150 mg/1 mL solution for subcutaneous injection in a pre-filled syringe, and a 300 mg/2 mL presentation. The 300 mg/2 mL strength is produced in very limited quantities, so in clinical practice the 150 mg/1 mL presentation is the one most commonly used. Secukinumab was the first fully human anti-IL-17A biologic approved worldwide, and in China it has been included in the national medical insurance drug list, which lowers the out-of-pocket cost for eligible patients. In China it is approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa.
What Is Secukinumab Used For?
Secukinumab is used to treat several immune-mediated inflammatory conditions driven by the IL-17 pathway. In China-Mainland, Cosentyx is indicated for adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, for active psoriatic arthritis, for active ankylosing spondylitis, for non-radiographic axial spondyloarthritis with objective signs of inflammation, and for hidradenitis suppurativa. It provides a biologic option for patients whose disease has not responded adequately to conventional treatment.
How Does Secukinumab Work?
Secukinumab is a fully human monoclonal antibody that binds selectively to interleukin-17A (IL-17A) and prevents it from interacting with the IL-17 receptor. IL-17A is a pro-inflammatory cytokine that plays a central role in the inflammation underlying psoriasis, psoriatic arthritis and axial spondyloarthritis. By neutralising IL-17A, secukinumab reduces the release of pro-inflammatory cytokines and chemokines, lowering neutrophil infiltration into psoriatic plaques and dampening the inflammatory process in the skin and joints.
Indications
In China-Mainland, Cosentyx (secukinumab) is indicated for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, for active psoriatic arthritis, for active ankylosing spondylitis, for non-radiographic axial spondyloarthritis with objective signs of inflammation, and for moderate-to-severe hidradenitis suppurativa. Treatment should be initiated and supervised by a physician experienced in diagnosing and treating these conditions.
Dosage
For plaque psoriasis, the recommended dose of secukinumab is 300 mg by subcutaneous injection at weeks 0, 1, 2, 3 and 4, followed by 300 mg every 4 weeks as maintenance. The 300 mg dose is given as two 150 mg injections. For psoriatic arthritis and ankylosing spondylitis, the dose is 150 mg by subcutaneous injection at weeks 0, 1, 2, 3 and 4, then 150 mg every 4 weeks. The medicine can be self-administered after appropriate training by a healthcare professional, and injections should be given in areas free of psoriatic plaques where possible. Because the 300 mg/2 mL strength is manufactured only in very small quantities, patients and institutions generally use the 150 mg/1 mL presentation.
Side Effects
The most commonly reported adverse reaction to secukinumab is upper respiratory tract infection, most often nasopharyngitis or rhinitis, which is generally mild to moderate. As exposure increases, the frequency of candida infections, herpes viral infections and staphylococcal skin infections may rise. Mild, transient and reversible neutropenia has been observed, and rare cases of urticaria and hypersensitivity reactions have been reported. Patients should watch for signs of infection and inform their doctor of any persistent or unusual symptoms.
Storage
Cosentyx should be stored under refrigeration at 2°C to 8°C, protected from light, in the original packaging, and must not be frozen or shaken. The pre-filled syringe contains no preservative and any unused portion must be discarded. The medicine should be kept out of the reach of children.
Why Choose the China Version of Cosentyx?
The China-Mainland Cosentyx is the locally registered, NMPA-approved presentation of secukinumab, backed by Novartis' global development programme and reimbursed through China's national medical insurance drug list. For patients and institutions seeking a reliable IL-17A biologic for psoriasis or spondyloarthritis, sourcing through GLT adds verification of authenticity, cold-chain integrity and the complete export documentation needed for cross-border procurement, keeping the process transparent and traceable.
How to Order
To source China-Mainland Cosentyx (secukinumab) through GLT, contact us on WhatsApp at +86 15234153837 or email [email protected]. Tell us the quantity and your destination, and we will confirm current stock, cold-chain logistics and the import documentation required. A valid prescription is required, and we serve both institutions and individual patients.
FAQ
What is the Chinese brand name of Cosentyx? In China, Cosentyx (secukinumab) is known as 可善挺 and is marketed by Novartis.
Is secukinumab covered by medical insurance in China? Yes. Secukinumab (Cosentyx) is listed in China's national medical insurance drug list, which lowers the out-of-pocket cost for eligible patients.
What conditions does Cosentyx treat? In China, Cosentyx is approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa.
How is secukinumab given? It is given by subcutaneous injection, with an initial loading phase at weeks 0, 1, 2, 3 and 4 followed by maintenance dosing every 4 weeks.
Is a prescription required? Yes. Cosentyx is a prescription biologic and must be used under the supervision of a physician.
What strengths of Cosentyx are available? Cosentyx (secukinumab) is available in a 150 mg/1 mL and a 300 mg/2 mL strength. The 300 mg/2 mL presentation is produced in very limited quantities, so the 150 mg/1 mL strength is the one most commonly used.